Millennix Report issue

For profit Phase 2
Founded: Rye Brook NY United States (1997)
Status: Acquired by Aptiv Solutions (2006) → now ICON (2014)

Organization Overview

First Clinical Trial
2000
NCT00009854
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (3)

bexarotene (targretin) (1 trial)

carmustine (bicnu) (2 trials)

methoxsalen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Central Nervous System Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Neoplasms (Phase 2)

Nervous System Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3